
    
      The study consisted of a 4-week screening period and a 26-week randomized treatment period
      (Primary Evaluation Period). After completion of the 26-week Primary Evaluation Period, all
      participants had the opportunity to enter the Extension Period, wherein participants will
      receive ravulizumab for up to 5 years.

      This study is ongoing. The data presented is for the Primary Evaluation Period. The results
      for the Extension Period will be reported after study completion.
    
  